CARVEDILOL (carvedilol) by Rubicon Biotechnology is adrenergic alpha-antagonists [moa]. Approved for essential hypertension [see ], cardiovascular mortality in clinically stable patients, without symptomatic heart failure) [see ] and 3 more indications. First approved in 2007.
Drug data last refreshed 20h ago
Adrenergic alpha-Antagonists
alpha-Adrenergic Blocker
Worked on CARVEDILOL at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract
Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients
Immediate Release Versus Slow Release Carvedilol in Heart Failure
Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension
Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension